ALTSTATION.IO

Henry Schein, Inc. (HSIC) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$78.73

Change

+2.25%

Market Cap

$9.55B

Avg Volume

1.2M

Company Overview

Henry Schein, Inc. is a leading provider of health care products and services, primarily focused on dental and medical practitioners. Based in Melville, New York, the company operates in three main segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. Its product lineup includes dental merchandise like handpieces and PPE, medical supplies such as pharmaceuticals and surgical products, and even practice management software. They cater to a diverse customer base, including dental and medical offices, laboratories, ambulatory surgery centers, and government clinics.

In terms of competitive position, Henry Schein is a market leader in the healthcare distribution space. It benefits from a broad product range and strong relationships with healthcare providers. However, it faces stiff competition from companies like McKesson and Cardinal Health, as well as rising niche players focusing on specific segments. Market dynamics, such as the shift toward value-based care and increased emphasis on cost efficiencies, could impact growth and margins.

As of now, Henry Schein is in a growth phase, focusing on expanding its service offerings and investing in technology. The company recently made strategic moves to enhance its digital capabilities, which are essential given the ongoing shift towards telehealth and digital solutions in healthcare. While the general market for medical distribution remains robust, maintaining innovation and adapting to evolving practitioner needs will be key for Henry Schein’s sustained growth.

Key Financials

Market Cap

$9.55B

Revenue

$12.94B

EBITDA

$1.01B

Gross Margin

31.2%

Profit Margin

3.0%

Revenue Growth

5.2%

Total Cash

$136.00M

Total Debt

$3.44B

Free Cash Flow

$285.12M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

24.84

Forward P/E

14.90

Beta

0.89

52-Week High

$81.35

52-Week Low

$60.56

EPS

$3.17

50-Day Avg

$76.16

200-Day Avg

$70.68

Price/Book

2.78

Technical Analysis

Over the past 52 weeks, Henry Schein, Inc. (HSIC) has exhibited a generally bullish trend, marked by a notable advance from a low of approximately $62 in late October to its current price of $78.73. Key resistance is identified at $79.72, reached in January, while support levels have formed around $70, particularly during the dips observed between March and April. The stock has shown evidence of a cup-and-handle pattern from late November through January, indicating bullish continuation potential. In recent weeks, the stock has demonstrated strong upward momentum, made evident by consecutive higher highs, reflecting increased buying pressure. Currently, with the price at $78.73, HSIC is trading just below its recent high, about 1.04% above its 52-week change and close to its upper range, suggesting that it could either break out or face selling pressure if it fails to confirm the advance above resistance.

Recent News and Developments

Here’s a summary of the latest news and developments for Henry Schein, Inc

(HSIC) stock in the past week:

1. Henry Schein Stock Reaches New 52-Week High

Henry Schein’s share price hit a new 52-week high on Friday, February 6, 2026. The stock traded as high as $80.98 and closed at $79.3130, following a previous close of $77.00. This upward movement reflects positive investor sentiment during the week.

2. Analysts Maintain “Hold” Rating Amidst Sector Stability Expectations

As of February 6, 2026, Henry Schein holds a consensus “Hold” rating from investment analysts, with an average target price of $76.42. While the broader dental sector hopes for stability in 2026 after a volatile 2025, analysts are cautiously optimistic, noting that trends leading to prior weaknesses appear to have stabilized.

Market Sentiment and Analyst Recommendations

Bull Case

Henry Schein just hit a 52-week high and broke out of a cup-and-handle pattern, which typically precedes further upside. The company is benefiting from sector stabilization after a rough 2025, and 5.2% revenue growth shows it’s still expanding despite competitive pressures in dental distribution. With $136M in cash and only $3.44B in debt, the balance sheet is solid enough to fund acquisitions or shareholder returns. The February 24 earnings call is the next catalyst, and if Q4 beats expectations, the stock could clear $81.35 resistance and run toward the $90 analyst target. Henry Schein One’s podcast and product promotions signal active engagement with customers, which matters in a sticky, recurring-revenue business like dental supplies.

Bear Case

The 24.84 P/E is expensive for a company growing at just 5.2%, especially when the broader market offers better growth at lower multiples. Consensus analyst target of $76.42 is actually below the current $78.73 price, meaning the street sees downside risk from here. The stock is trading at the upper end of its 52-week range with resistance at $79.72, so any miss on earnings could trigger a fast reversal back toward $70 support. Revenue growth is sluggish, suggesting limited pricing power or market share gains in a mature dental supply market. The hold rating from 14 analysts reflects genuine uncertainty about the company’s ability to accelerate growth, not conviction.

What to Watch

Q4 2025 earnings on February 24 are critical. Watch for revenue beat/miss versus expectations and any guidance changes for 2026 growth rates. If HSIC confirms revenue acceleration above 6% or provides upside guidance, it could break through $81.35 and retest $85. Conversely, if Q4 disappoints or management guides lower, expect a drop back to $70-72 support. Monitor the debt-to-EBITDA ratio and free cash flow generation over the next two quarters to assess whether the company can fund growth or will face refinancing pressure. Track dental market utilization rates and customer acquisition costs in the earnings commentary, as these directly impact Henry Schein’s pricing power and margin expansion potential.

Analyst Consensus

HOLD

Based on 14 analyst opinions

Low Target

$58.00

Mean Target

$78.14

High Target

$90.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Distribution

Employees

25,000

Earnings & Dividends

Next Earnings

Feb 24, 2026

EPS (Trailing)

$3.17

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is HSIC a good stock to buy?

With a current price of $78.73 and a HOLD recommendation from analysts, HSIC isn’t seen as a strong buy right now. The stock is within its 52-week range and shows moderate P/E ratios, indicating it’s fairly valued at best.

What is HSIC’s price target?

Analysts have a price target of $78.14 for HSIC, which suggests a slight downside from its current price. This target aligns with the HOLD recommendation, indicating limited upside potential in the near term.

Does HSIC pay a dividend?

HSIC does not pay a dividend. For investors looking for income through dividends, this stock may not be an attractive choice.

What are HSIC’s valuation metrics?

HSIC has a P/E of 24.84 and a forward P/E of 14.90. These metrics suggest that while it might be overvalued compared to its earnings, the lower forward P/E indicates potential for future growth.

How does HSIC perform compared to its 52-week range?

HSIC’s price is currently near the upper end of its 52-week range of $60.56 to $81.35. This suggests that the stock could be fairly valued with little room for growth unless positive catalysts arise.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.